欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
DRF-1042_200619-13-2_产品详情
200619-13-2
  • names:

    DRF-1042

  • CAS号:

    200619-13-2

    MDL Number:
  • MF(分子式): C22H20N2O6 MW(分子量): 408.4
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
DRF-1042
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM000896-5mg 5mg 98.04% ¥ 6183.00 ¥ 6183.00 2-3天
- +
¥ 0.00
YZM000896-1mg 1mg 98.04% ¥ 1976.00 ¥ 1976.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名 DRF-1042
CAS号 200619-13-2
Inchi
InchiKey
分子式 Formula C22H20N2O6
分子量 Molecular Weight 408.4
溶解度Solubility
性状
储藏条件 Storage conditions -20°C, stored under nitrogen * In solvent : -80°C, 6 months月; -20°C, 1 month月 (stored under nitrogen)
产品说明
IntroductionDRF042 is an orally active derivative of Camptothecin. DRF042 acts to inhibitDNA topoisomerase I. DRF042 shows good anticancer activity against a panel of human cancer cell lines including multirug resistance (MDR) phenotype[2].
Application1
Application2
Application3
DRF-1042 是一种有效的具有口服活性的喜树碱类似物,具有抑制 DNA 拓扑异构酶 I (DNA topoisomerase I) 的作用。DRF-1042 对一组人癌细胞株,包括多药耐药 (MDR)表型,显示出良好的抗癌活性。DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibitDNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype[1][2].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.
【2】.Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents